UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of Earliest Event Reported): |
October 3, 2006 |
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
000-50513 |
13-3831168 |
|
(State or other jurisdiction |
(Commission |
(I.R.S. Employer |
|
of incorporation) |
File Number) |
Identification No.) |
|
|
|
|
|
15 Skyline Drive, Hawthorne, NY |
|
10532 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
Registrant’s telephone number, including area code: |
(914) 347-4300 |
|
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
Attached hereto as Exhibit 10.44 and incorporated herein by reference is the Securities Purchase Agreement by and among Acorda Therapeutics, Inc (the “Registrant”) and the purchasers set forth on Exhibit A thereto (the “Securities Purchase Agreement”), which includes corrected signature pages and replaces the Securities Purchase Agreement filed as Exhibit 10.44 on the Current Report Form 8-K dated October 5, 2006.
Item 3.02 Unregistered Sales of Equity Securities
On October 6, 2006, the Registrant completed the previously disclosed issuance of common stock of the Registrant in a private placement on the terms set forth in the Securities Purchase Agreement.
Item 9.01 Financial Statements and Exhibits
10.44 Securities Purchase Agreement, dated October 3, 2006, by and among Acorda Therapeutics, Inc. and the purchasers listed on Exhibit A thereto.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Acorda Therapeutics, Inc. |
|
|
|
|
|
|
October 6, 2006 |
By: |
/s/ David Lawrence |
|
|
|
|
|
|
|
Name: David Lawrence |
|
|
|
Title: Chief Financial Officer |
3
Exhibit Index
|
Exhibit No. |
Description |
|
10.44 |
Securities Purchase Agreement, dated October 3, 2006, by and among Acorda Therapeutics, Inc. and the purchasers listed on Exhibit A thereto. |
4